Après délibération, le collège de la Haute Autorité de santé, en sa séance du 10 novembre 2022 a constaté l'absence d’évaluation médico-économique du produit TECARTUS (brexucabtagene autoleucel).
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
9qAWkZ8t0RXxjbbB
